Research programme: cancer and inflammation therapeutics - Xcovery

Drug Profile

Research programme: cancer and inflammation therapeutics - Xcovery

Alternative Names: X-339; X-376; X-379; X-414; X-480

Latest Information Update: 06 Oct 2016

Price : $50

At a glance

  • Originator Xcovery
  • Developer Xcovery Holdings
  • Class Pyrazolones; Pyrimidines; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Hepatocyte growth factor inhibitors; MTOR protein inhibitors; P38 mitogen-activated protein kinase inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preclinical Cancer
  • Discontinued Inflammation

Most Recent Events

  • 05 Oct 2016 Discontinued for Inflammation in USA (PO)
  • 05 Oct 2016 Preclinical development is ongoing for cancer in USA (Xcovery pipeline, October 2016)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top